Plain-English translation of NCT04866654 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for early-stage Hodgkin lymphoma that avoids radiation. After you receive standard chemotherapy, doctors will use imaging scans to see how well the cancer is responding. If your cancer responds well, you may receive Nivolumab—an immunotherapy medication that helps your immune system fight cancer cells—for one year instead of undergoing radiation therapy.
Radiation therapy can cause serious long-term side effects like heart problems and secondary cancers, especially in younger patients. This trial is exploring whether this medication can safely replace radiation in patients whose cancer responds well to chemotherapy, potentially protecting patients from these late complications while still controlling their disease.
You will first receive standard chemotherapy over several cycles while the study team monitors your response using imaging scans. If your cancer shows a good response, you will then receive the immunotherapy medication as an infusion, typically over one year of maintenance treatment. Throughout the study, you'll have regular blood tests and imaging scans, and you'll be asked to participate in long-term follow-up for over ten years to track your health and watch for any late side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Italy